D.H.E. 45
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
D.H.E. 45 is a long-standing injectable product first approved in 1946 by Bausch + Lomb. The specific indication and mechanism of action are not documented in available data, limiting assessment of its therapeutic positioning. As an older NDA, it represents a legacy small-molecule injectable in the modern formulary.
LOE Approaching
Product is in late-stage decline with minimal linked job activity, indicating a small or transitioning commercial team focused on legacy product management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on D.H.E. 45 offers limited growth potential given zero linked job openings and approaching LOE. Career value lies in legacy brand management, cost defense, and transition planning rather than innovation or expansion.
Field SalesAccount Manager
Worked on D.H.E. 45 at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.